Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and tirzepatide are primarily used in the treatment of type 2 diabetes and obesity. Beyond correcting metabolic imbalance, these agents modulate the tumor microenvironment, enhance apoptosis, downregulate pro-inflammatory signaling, and impair metastatic potential in cancer cells. The primary objective of this review is to evaluate the impact of incorporating incretin-based therapies into the management of gynecologic malignancies, including endometrial, ovarian, and cervical cancers. In endometrial cancer, GLP-1RAs and tirzepatide promote apoptosis, reverse chemoresistance, enhance progesterone receptor signaling, and demonstrate synergy with hormonal therapies. In ovarian cancer, GLP-1RAs have been shown to suppress tumor-promoting pathways, reduce inflammation, and inhibit metastatic processes. In cervical cancer, particularly among patients with type 2 diabetes, GLP-1RAs may offer protective effects by counteracting the pro-inflammatory and tumor-promoting effects of hyperglycemia. GLP-1RAs and tirzepatide target metabolic dysregulation and directly modulate signaling pathways involved in tumorigenesis, which may help redefine existing clinical approaches in gynecologic oncology by combining metabolic control with antineoplastic activity.